A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes

Summary What is known and objective Inhibition of the fibrinolytic system may occur at the level of plasminogen activation, mainly by PAI‐1. Mental and physical stress caused to alterations of platelet function, and also decreased to fibrinolytic activity. Furthermore, stress‐induced thrombosis regu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacy and therapeutics 2017-02, Vol.42 (1), p.103-107
Main Authors: Yenilmez, C., Ozdemir Koroglu, Z., Kurt, H., Yanas, M., Colak, E., Degirmenci, I., Gunes, H. V.
Format: Article
Language:English
Subjects:
Adult
Alleles
Case-Control Studies
Diagnostic and Statistical Manual of Mental Disorders
Female
Gene Frequency - genetics
Genetic Predisposition to Disease - genetics
Genotype
Humans
Male
Middle Aged
Mutagenesis, Insertional - genetics
PAI‐1 4G/5G polymorphism
Plasminogen Activator Inhibitor 1 - genetics
Promoter Regions, Genetic - genetics
schizophrenia
Schizophrenia - genetics
Sequence Deletion - genetics
Turkey
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary What is known and objective Inhibition of the fibrinolytic system may occur at the level of plasminogen activation, mainly by PAI‐1. Mental and physical stress caused to alterations of platelet function, and also decreased to fibrinolytic activity. Furthermore, stress‐induced thrombosis regulation was proposed to be by PAI‐1 in schizophrenia patients. In this study, the distribution of genotypes and frequency of alleles of the plasminogen activator inhibitor type 1 (PAI‐1) gene 4G/5G polymorphism in different Turkish clinical schizophrenia subtypes was investigated for its role in schizophrenia development. Methods The clinical schizophrenia subtypes include paranoid, catatonic, disorganized, undifferentiated and residual, as diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders‐Fourth Edition IV (DSM‐IV). Samples of genomic DNA (250 total, including 150 schizophrenia patients and 100 healthy subjects) were analysed. PAI‐1 4G/5G genotyping was performed by polymerase chain reaction–allele‐specific amplification. PCR products were separated by 2% agarose gel electrophoresis and then visualized. Results and discussion The genotype distributions (P = 0·136) and allele frequencies (P = 0·721 for 4G, P = 0. 097 for 5G) were not significantly different between patients with schizophrenia and control subjects for the 4G/5G polymorphism. Similar results were also found for the genotype distributions (P = 0·640) and allele frequencies (P = 0·763 for 4G, P = 0·448 for 5G) in the clinical schizophrenia subtypes compared to the each other. What is new and conclusion We conclude that PAI‐1 4G/5G polymorphism was not significantly associated with schizophrenia or its subtypes in the Turkish population. However, we recognize that with our sample sizes, we cannot exclude weak associations. We investigated PAI‐1 gene 4G/5G polymorphism in different Turkish schizophrenia subtypes for role in its development. In conclusion any significant difference in the prevalence of PAI‐1 4G/5G polymorphism wasn't investigated even when different schizophrenic subtypes were compared.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.12470